Shaping the Future of Neurodegenerative Diseases:
Avertim's Strategic Journey with the European Platform for Neurodegenerative Diseases (EPND)
Throughout the years, Avertim has been actively engaged in several projects focused on the scale-up of external innovation within the context of public-private partnerships (PPPs). In these partnerships, industry, academia, and public partners unite in the pursuit of common research or development goals.
With millions globally affected by Neurodegenerative diseases and with no effective treatments on the market, in 2023, our focus centered on the European Platform for Neurodegenerative Diseases (EPND). EPND is a PPP comprised of 29 partners with the mission to reshape the future of neurodegenerative diseases by breaking down barriers to data sharing to accelerate the discovery and development of new diagnostics and therapeutics.
As EPND aims to transition from a funded PPP to a scalable self-driven entity, critical questions and challenges arise on the horizon. Which services should they offer to capture their target audience and to maximize impact? How should this entity operate? How to build a sustainable business model?
Representing one of the industry partners within this PPP, Avertim leveraged its unique experience in Lifesciences and management consulting to address these pivotal questions and navigate the neurodegenerative landscape.
Our “advise” delivery mode and experience in the “digital and analytics service line” enabled our team to embark on a strategic benchmarking initiative of the neurodegenerative data landscape. The identified key trends, potential strategic partnerships, and opportunities to position EPND in the market combined with input from face-to-face workshops with the other partners laid the foundation for potential business and operating models that will further be explored in 2024.
As we approach 2024, we are looking forward to delving deeper into EPND’s pivotal questions proud to getting another step closer and contributing to a self-driven entity that will reshape the future of neurodegenerative diseases. Want to know more about our methodologies? Feel free to contact us!
Written by
Valérie Neven, Engagement Manager